Immunodiagnostics or immunoassay is a key technique of in vitro diagnostics that deals with the diagnosis of various diseases based on antigen-antibody reaction. Immunodiagnostics is an analytical technique, which employs antibodies as reagents against the antigens to be detected. The result of immunodiagnostics test aids in diagnosing. It also has clinical application in the field of infectious diseases, oncology & endocrinology, hepatitis & retrovirus, bone & mineral, autoimmunity, cardiac biomarker, and others. The test is usually performed in laboratories and hospitals from patient's biological specimen such as blood, urine, stool, or other body fluid to detect diseased condition and infection.
The key drivers for the market growth include rise in incidence of chronic and infectious diseases along with the growth in geriatric population, technological advancements such as fully automated and more capable immunoassay platforms and increase in need for accurate, target specific, and rapid diagnostic tests. In addition, rise in demand for next generation immunodiagnostics platform and popularity of personalized medicine is poised to augment the growth of immunodiagnostics market globally. However, high cost of sophisticated immunodiagnostics test, stringent government regulations, and reluctance in adoption of advanced technologies in emerging economies are few factors that impede the market growth. The world immunodiagnostics market is projected reach $17,836 Million by 2022, from $10,738 Million growing at a CAGR of 7.3% from 2016 to 2022
The world immunodiagnostics market is segmented on the basis of product, technology, application, end user, and geography. Based on product, the market is divided into reagents, instruments, and services & software. Reagents segment has the largest market share, owing to high cost of the immunoassay reagents (such as enzyme and substrate) and technological advancements in reagents for accurate and specific results. Based on technology, the market is segmented into enzyme-linked immunosorbent assay (ELISA), chemiluminescence immunoassay (CLIA), fluorescent immunoassay (FIA), radioimmunoassay (RIA), rapid test, and others. ELISA holds the highest share in the technology market owing to the technological advancements such as automated platforms for ELISA, continues development in biomarkers and cost benefits. Nevertheless, CLIA exhibit the highest growth owing to the technological innovation such as automated platforms offering highly accurate results. Based on application, the immunodiagnostics market is classified into infectious diseases, oncology & endocrinology, hepatitis & retrovirus, bone & mineral, autoimmunity, cardiac biomarker, and others. Among these, infectious disease segment is the highest revenue contributor, while oncology & endocrinology segment grow at a fastest rate, during the forecast period. On the basis of end user, the immunodiagnostics market is segmented into hospitals, laboratories, academics & research universities, pharma & biotech industries among others.
The geographical segmentation of the market includes North America, Europe, Asia-Pacific, and LAMEA. In 2015, North America accounted for the largest market share in the immunodiagnostics market and is estimated to retain its dominant position throughout the forecast period. The growth in this region is mainly due to the factors such as product innovations, sophisticated healthcare infrastructure, U.S.-being the target area for the top players in the market owing to high prevalence rate of chronic diseases and increase in geriatric population. Nevertheless, Asia-Pacific region is expected to emerge as the area with maximum growth potential due to the rise in number of infectious diseases, increase in chronic diseases, presence of high unmet needs, and increased focus of key players towards emerging markets such as China and India, and increased healthcare expenditure for the development of improved healthcare infrastructure.
Product development and launch is the mostly adopted strategy in the immunodiagnostics market followed by acquisition. The report provides a comprehensive analysis of the key players that operate in the world immunodiagnostics market.
KEY MARKET BENEFITS
The study provides an in-depth analysis of the world immunodiagnostics market with current trends and future estimations to elucidate the imminent investment pockets.
The report provides a quantitative analysis from 2014 to 2022 to enable the stakeholders to capitalize on prevailing market opportunities.
Extensive analysis of the market, by product, helps understand various types of devices used for the treatment of infectious diseases, oncology & endocrinology, hepatitis & retrovirus, bone & mineral, autoimmunity, cardiac biomarker, and others.
Competitive intelligence highlights the business practices followed by the leading market players across various geographies.
Porters Five Force's model will interpret the bargaining power of suppliers and buyers, threat of new entrants and substitutes, and competition amongst the key players.
KEY MARKET SEGMENTS
By Product
Reagents
Instruments
Software & Services
By Technology
Enzyme-Linked Immunosorbent Assay (ELISA)
Chemiluminescence Immunoassay (CLIA)
Fluorescent Immunoassay (FIA)
Radioimmunoassay (RIA)
Rapid Test
Others
By Application
Infectious Diseases
Oncology & endocrinology
Hepatitis & retrovirus
Bone & mineral
Autoimmunity,
Cardiac biomarker
Others
By End User
Clinical Laboratories
Hospitals
Academic & Research Centers
Pharmaceutical & Biotechnology Industry
Others
By Geography
North America
U.S.
Canada
Mexico
Europe
U.K.
France
Germany
Rest of Europe
Asia-Pacific
Japan
China
India
Australia
Rest of Asia-Pacific
LAMEA
Latin America
Middle East
Africa
KEY PLAYERS
Abbott Laboratories
Immunodiagnostic Systems Holdings Plc (IDS)
DiaSorin S.p.A.
Johnson & Johnson
F. Hoffmann-La Roche Ltd
Siemens AG
Sysmex Corporation
Danaher Corporation
Thermo Fisher Scientific Inc.
Bio-Rad Laboratories, Inc.
Arkray, Inc.
Other players in the value chain include (profiles not included in the report)
Arkray, Inc.,
Alere, Inc.,
Merck Millipore,
Becton, Dickinson and Company,
Biomerieux SA,
Medicaroid Corporation,
Qiagen NV,
Affimetrix,
ImmunoDX,
Meridian Bioscience